Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10250531 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL4760522 | 0.94 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2787104 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL9906942 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15841156 | 0.89 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15841157 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL12683472 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL13621944 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18084803 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL13547248 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | SMN1; SMN2 2834/4885NPC1 197/4885RAB9A 772/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | SMN1; SMN2 2983/4885NPC1 162/4885RAB9A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.